Nektar Therapeutics (NKTR)

31.19
2.19 6.56
NASDAQ
Prev Close 33.38
Open 33.54
Day Low/High 31.16 / 33.90
52 Wk Low/High 29.22 / 111.36
Volume 2.02M
Exchange NASDAQ
Shares Outstanding 174.10B
Market Cap 5.81B
Div & Yield N.A. (N.A)
What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

Amazon seems nearly unstoppable, says Jim Cramer. So be careful if you own something that could be in the retail giant's crosshairs.

Nektar Therapeutics Presents Preclinical Data On Its Immuno-Oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics Presents Preclinical Data On Its Immuno-Oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist, and NKTR-255,...

Vaccibody AS And Nektar Therapeutics Present New Preclinical Data From Their Immuno-Oncology Collaboration At The American Association For Cancer Research (AACR) Annual Meeting 2019

Vaccibody AS And Nektar Therapeutics Present New Preclinical Data From Their Immuno-Oncology Collaboration At The American Association For Cancer Research (AACR) Annual Meeting 2019

OSLO, Norway and SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.

Nektar Therapeutics To Webcast Presentation At The Cowen And Company 39th Annual Health Care Conference

Nektar Therapeutics To Webcast Presentation At The Cowen And Company 39th Annual Health Care Conference

SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.

Nektar Therapeutics Presents Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of The REVEAL Study At 2019 ASCO-SITC Meeting

Nektar Therapeutics Presents Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of The REVEAL Study At 2019 ASCO-SITC Meeting

SAN FRANCISCO, March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262, a...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADSK, BDC, HLNE, HRI, NKTR, SNV Downgrades: AYX, HMN, IDCC, TPRE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Reports Fourth Quarter And Year-End 2018 Financial Results

Nektar Therapeutics Reports Fourth Quarter And Year-End 2018 Financial Results

SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018.

Nektar Therapeutics Becomes #3 Most Shorted S&P 500 Component, Replacing Iron Mountain

Nektar Therapeutics Becomes #3 Most Shorted S&P 500 Component, Replacing Iron Mountain

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Nektar Therapeutics Announces Several Preclinical Data Presentations For Its Immuno-oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics Announces Several Preclinical Data Presentations For Its Immuno-oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

SAN FRANCISCO, Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist,...

Nektar Therapeutics Expected to Lose 55 Cents a Share

Nektar Therapeutics Expected to Lose 55 Cents a Share

Nektar Therapeutics revenue expected to fall 53% to $44.8 million.

Nektar Therapeutics To Webcast Conference Call For Analysts And Investors At The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Nektar Therapeutics To Webcast Conference Call For Analysts And Investors At The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr.

Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2018 On Thursday, February 28, 2019, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2018 On Thursday, February 28, 2019, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Feb. 21, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February 28, 2019, after the close of U.

Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed The Company According To Shareholder Lawsuit

Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed The Company According To Shareholder Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nektar Therapeutics.

Clinical Data Presented From PIVOT-02 Study Of Bempegaldesleukin (NKTR-214) With Nivolumab In Metastatic Urothelial Carcinoma Patients At The 2019 ASCO Genitourinary Cancers Symposium

Clinical Data Presented From PIVOT-02 Study Of Bempegaldesleukin (NKTR-214) With Nivolumab In Metastatic Urothelial Carcinoma Patients At The 2019 ASCO Genitourinary Cancers Symposium

Analyst conference call with urothelial cancer specialist to be held at 2:00 p.m. Pacific Time today

Nektar Therapeutics To Webcast Conference Call With Urothelial Cancer Specialist For Analysts & Investors At The 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics To Webcast Conference Call With Urothelial Cancer Specialist For Analysts & Investors At The 2019 ASCO Genitourinary Cancers Symposium

SAN FRANCISCO, Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.

The New #12 Most Shorted S&P 500 Component: Nektar Therapeutics

The New #12 Most Shorted S&P 500 Component: Nektar Therapeutics

The most recent short interest data has been released for the 12/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

I see a lot of winners here because of hindsight.

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines

Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 37th Annual J.P. Morgan Healthcare Conference In San Francisco, CA

Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 37th Annual J.P. Morgan Healthcare Conference In San Francisco, CA

SAN FRANCISCO, Dec. 27, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 37th Annual J.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Nektar securities between November 11, 2017 through...

NKTR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR

NKTR ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017 through October...

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Nektar Therapeutics, Inc.

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Nektar Therapeutics (NKTR) And December 31 Lead Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Nektar Therapeutics (NKTR) And December 31 Lead Plaintiff Deadline

NEW YORK, Nov. 27, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or...

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors Of Important Deadline In Class Action Seeking Investor Losses - NKTR

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period") of the important December 31, 2018 lead plaintiff...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that...

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Nektar Appoints Wei Lin, M.D., As Senior Vice President Of Clinical Development And Head Of Nektar's Oncology Programs

Nektar Appoints Wei Lin, M.D., As Senior Vice President Of Clinical Development And Head Of Nektar's Oncology Programs

SAN FRANCISCO, Nov. 14, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.

Nektar Therapeutics Presents New Clinical And Preclinical Data For Its Immuno-Oncology Pipeline At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

Nektar Therapeutics Presents New Clinical And Preclinical Data For Its Immuno-Oncology Pipeline At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

New Efficacy, Safety and Biomarker Data Presented for Stage IV I-O Naïve Melanoma Patients in PIVOT-02 Study of NKTR-214 with nivolumab

TheStreet Quant Rating: C (Hold)